SCHEMBL2904846

SCHEMBL2904846

CN1CCC(N(C)Cc2cn(-c3ccc(-c4ccc5c(c4)OCCO5)cc3)nc2-c2ccco2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.42
LMNA P02545 3/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
HSD17B10 Q99714 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
KDM4E B2RXH2 14/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
KMT2A Q03164 7/20 0.39
MEN1 O00255 6/20 0.39
MAPT P10636 4/20 0.39
POLB P06746 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
TSHR P16473 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
NFKB1 P19838 1/20 0.37
NFKB2 Q00653 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902352 0.87 ALDH1A1 (0.45) ALDH1A1LMNANPC1GAAMAPK1
SCHEMBL2904628 0.85 KDM4E (0.51) ALDH1A1LMNANPC1RAB9AGAA
SCHEMBL2902342 0.85 ALDH1A1 (0.54) ALDH1A1NPC1RAB9AHSD17B10GAA
SCHEMBL2902223 0.77 ALDH1A1 (0.54) ALDH1A1LMNANPC1RAB9AHSD17B10
SCHEMBL2908333 0.77 KDM4E (0.51) ALDH1A1LMNANPC1RAB9AHSD17B10
SCHEMBL2904990 0.76 KDM4E (0.55) ALDH1A1LMNANPC1RAB9AHSD17B10
SCHEMBL2907697 0.75 ALDH1A1 (0.58) ALDH1A1LMNANPC1RAB9AHSD17B10
SCHEMBL2904847 0.75 ALDH1A1 (0.33) ALDH1A1NPC1HTTKDM4EMAPT
SCHEMBL2901684 0.75 ALDH1A1 (0.56) ALDH1A1LMNANPC1RAB9AHSD17B10
SCHEMBL2904795 0.75 ALDH1A1 (0.52) ALDH1A1LMNANPC1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed
EP-1611107-A1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GmbH (DE) 2006-01-04 EP disclosed
WO-2004089910-A1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885LMNA 3014/4885NPC1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.